Bio Green Med Solution gets Nasdaq bid price deficiency notice

Bio Green Med Solution, Inc. disclosed in an 8-K filed for an October 29, 2026 event that it received a written notice from the Nasdaq Stock Market LLC stating that the closing bid price of its common stock had stayed below $1.00 per share for 30 consecutive business days, falling short of the minimum bid price standard under Nasdaq Listing Rule 5550(a)(2), which triggered an automatic 180-day grace period for the company to regain compliance.¹

The company said the notice has no immediate effect on the listing or trading of its common stock, which will keep trading on Nasdaq under the ticker "BGMS."¹ Under Nasdaq rules, the company has until April 27, 2027 to regain compliance, which it can do if the stock's closing bid price reaches $1.00 or more for at least 10 consecutive business days before that date.¹

If compliance is not achieved in time, Nasdaq would issue a delisting notice, though the company could then appeal that determination to a hearings panel.¹

The notice comes amid a pending business combination. On June 4, 2026, the company entered into a Business Combination Agreement with Future NRG Sdn. Bhd., a Malaysian private limited company, and its shareholders, under which those shareholders will exchange their FNRG shares for Bio Green Med Solution common stock, making FNRG a wholly owned subsidiary of the company.¹ Related to that deal, the company filed a Form S-4 on June 26, 2026, declared effective by the SEC on October 8, 2026, which includes a proposal for a reverse stock split at a ratio between 1-for-4 and 1-for-16, to be set by the board.¹

The company said it plans to keep monitoring its bid price and will consider options, including a reverse stock split, to regain compliance within the initial 180-day period as part of closing the transaction, while cautioning there is no assurance stockholders will approve the reverse split proposal or that compliance will be achieved.¹